Stopping Strattera: A Clinician’s Guide to Discontinuing Atomoxetine, Withdrawal and Rebound Symptoms, the Taper Protocol, and What to Expect Over the Following Weeks

What atomoxetine (Strattera) is and how it differs from stimulant ADHD medications, why people stop the medication, whether a taper is necessary, the withdrawal-like and rebound symptoms that can emerge, how to manage them safely, the timeline of return of ADHD symptoms, and what alternatives exist for ongoing ADHD treatment.

Clinically reviewed by Dr. Ponlawat Pitsuwan, Physician and Addiction Medicine Specialist, Phuket Island Rehab.

Strattera is the brand name for atomoxetine, a non-stimulant medication FDA-approved for the treatment of attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults. The medication works by selectively inhibiting the norepinephrine reuptake transporter, increasing synaptic norepinephrine in the prefrontal cortex and producing modest improvement in attention, focus, and impulse control over four to eight weeks of consistent use. Unlike stimulant medications including Adderall, Ritalin, Vyvanse, and Concerta, atomoxetine is not a controlled substance, does not produce the rapid euphoric effects that drive stimulant abuse, and is not associated with the classic dependence and withdrawal syndromes of the stimulant class. Stopping Strattera does not produce the severe withdrawal that follows discontinuation of stimulants, opioids, or benzodiazepines, but it can produce a discontinuation syndrome with rebound symptoms including return of the original ADHD symptoms, mood changes, irritability, fatigue, sleep disturbance, and occasionally headache, dizziness, or gastrointestinal upset. A gradual taper over two to four weeks under medical supervision is generally recommended, particularly for patients who have been on the medication for months to years or who are on higher doses. The taper protocol involves reducing the daily dose by 25 to 50 percent every 5 to 7 days based on tolerability. Alternative ADHD treatments can be initiated during or after the taper depending on individual clinical circumstances.

What Strattera is and how it differs from stimulant ADHD medications

Strattera is the brand name for atomoxetine, a selective norepinephrine reuptake inhibitor first approved by the U.S. Food and Drug Administration in 2002 for the treatment of attention deficit hyperactivity disorder in children, adolescents, and adults. The medication was the first non-stimulant ADHD treatment to gain FDA approval and remains one of the most widely used non-stimulant alternatives to the amphetamine and methylphenidate classes. Generic atomoxetine has been available since 2017 in the United States and is pharmacologically equivalent to brand-name Strattera at substantially lower cost.

The medication is not classified as a controlled substance by the Drug Enforcement Administration, in contrast to stimulant ADHD medications, which are Schedule II controlled substances with substantial abuse potential. The non-controlled status reflects the absence of the rapid euphoric effects that drive stimulant abuse and the absence of the classic dependence pattern. Patients can fill prescriptions for atomoxetine in standard pharmacy ways, refills can be authorised by phone in most jurisdictions, and there are no DEA restrictions on the duration of prescriptions or the number of refills.

Atomoxetine works through a different mechanism from the stimulant medications. The stimulants increase synaptic dopamine and norepinephrine through multiple mechanisms including blockade of the reuptake transporters and direct release of stored neurotransmitter from the presynaptic terminal. Atomoxetine selectively inhibits the norepinephrine transporter without significantly affecting dopamine transport in most brain regions, with the exception of the prefrontal cortex where the relative scarcity of dopamine transporters means that the norepinephrine transporter inhibition also produces some increase in extracellular dopamine. The result is improvement in ADHD symptoms through a more circumscribed neurochemical mechanism than the broader effects of stimulants.

The clinical effects develop more slowly than with stimulants. While a stimulant produces noticeable improvement within hours of the first dose, atomoxetine typically requires four to eight weeks of consistent daily dosing before the full clinical effect develops. The slower onset is one of the main reasons that patients sometimes discontinue the medication before reaching the therapeutic effect, mistakenly concluding that it does not work. Patients starting atomoxetine should be informed about the gradual onset and encouraged to continue for at least eight weeks before making any judgement about effectiveness.

Why people stop taking Strattera

Several common reasons lead patients to consider stopping Strattera. The most common is that the medication did not produce sufficient improvement in ADHD symptoms to justify continued use. Atomoxetine is generally considered less effective than the stimulant medications for ADHD symptom control, with effect sizes approximately 60 to 70 percent of the effect sizes for stimulants in most clinical trials. Patients whose ADHD symptoms remain prominent despite adequate dosing and adequate trial duration may reasonably consider switching to a stimulant or to a different non-stimulant medication.

A second common reason is side effects that the patient or family find unacceptable. The most common side effects of atomoxetine include nausea, abdominal pain, decreased appetite, fatigue, drowsiness, dizziness, mood changes, and sexual side effects including reduced libido and erectile dysfunction. Most of these diminish over the first weeks of treatment but some patients have persistent troublesome side effects despite dose adjustment. The medication carries a boxed warning about increased risk of suicidal thinking in children and adolescents, and any emergence of suicidal thoughts is a reason for immediate clinical reassessment.

A third reason involves life changes that make continued treatment unnecessary or impractical. Children and adolescents whose ADHD symptoms are well-controlled may transition off medication after a successful school year. Adults whose symptoms have improved through behavioural skills training, environmental adjustments, or life changes may consider discontinuation. Patients planning pregnancy may wish to stop the medication, though atomoxetine is FDA pregnancy category C and the decision should be made with attention to the risks of both treated and untreated ADHD during pregnancy.

A fourth reason involves changes in healthcare access, insurance coverage, or cost considerations. The transition from a stable medication regimen for cost reasons is unfortunate but common and warrants careful planning to manage the discontinuation safely. Patients who have been on atomoxetine should not simply stop refilling without discussion with their prescribing clinician, regardless of the reason for discontinuation.

Is a taper necessary when stopping Strattera?

Whether a formal taper is required when stopping atomoxetine is a clinical judgement based on the dose, the duration of treatment, and individual factors. Atomoxetine is not associated with the severe withdrawal syndromes that follow discontinuation of stimulants, opioids, benzodiazepines, or alcohol, all of which can produce medically significant or potentially dangerous withdrawal. The medication does not produce physical dependence in the classical sense, and abrupt discontinuation in patients on standard doses is not medically dangerous in healthy adults.

Despite the absence of medically dangerous withdrawal, atomoxetine discontinuation can produce a discontinuation syndrome similar in pattern (though usually milder) to the discontinuation syndromes of SSRI and SNRI antidepressants. The norepinephrine system has adapted to the presence of the medication, and abrupt cessation produces a period of relative norepinephrine deficit before the system returns to baseline. The symptoms can include fatigue, sleep disturbance, irritability, mood changes, headache, dizziness, sweating, and gastrointestinal symptoms. The symptoms are typically mild to moderate, are not dangerous, but can be unpleasant enough to justify a gradual taper.

Standard clinical practice is to taper atomoxetine over two to four weeks for patients who have been on the medication for more than a few months, with longer tapers for patients on higher doses or with longer treatment durations. The taper protocol typically involves reducing the daily dose by 25 to 50 percent every five to seven days, with adjustments based on tolerability. For example, a patient on 80 milligrams daily might reduce to 60 milligrams for one week, then 40 milligrams for one week, then 20 milligrams for one week, then stop. Patients tolerating the taper well can move through it more quickly; patients with troublesome symptoms can extend the taper or pause at a given dose level.

Patients who have been on atomoxetine for only a few weeks, particularly those who never reached therapeutic effect, can often stop without a formal taper. The brain has not had time to fully adapt to the medication and abrupt discontinuation typically produces minimal discontinuation symptoms. The clinical judgement should still involve discussion with the prescribing clinician rather than simply stopping without notice.

Withdrawal and rebound symptoms: what to expect

The discontinuation symptoms from stopping atomoxetine fall into two broad categories: pharmacological withdrawal symptoms reflecting the brain’s adaptation to the medication, and rebound symptoms reflecting the return of the underlying ADHD or other conditions that the medication was treating. The two overlap and can be difficult to distinguish in the first weeks after discontinuation.

Pharmacological withdrawal symptoms typically begin within the first few days after stopping or substantially reducing the dose and resolve over one to three weeks. The most common include fatigue, sleep disturbance with difficulty falling asleep or maintaining sleep, headache, dizziness, sweating, irritability, mood swings, and gastrointestinal upset including nausea and abdominal discomfort. Some patients describe a flu-like feeling or a sense of being unwell that they cannot fully characterise. The symptoms are real but are not medically dangerous and resolve as the brain readjusts to the absence of the medication.

Rebound symptoms involve the return of the original ADHD symptoms that the medication was treating. Inattention, difficulty concentrating, impulsivity, distractibility, restlessness, and the executive function difficulties characteristic of ADHD all return as the medication is withdrawn. The rebound can begin within days of dose reduction and is typically complete within two to four weeks of full discontinuation, depending on how long it takes for the medication to be cleared from the brain. The symptoms in this phase are essentially the same symptoms the patient had before starting treatment, sometimes feeling more prominent because of the contrast with the treated state.

Mood symptoms during atomoxetine discontinuation can include depression, anxiety, irritability, and emotional lability. The medication has some antidepressant and anti-anxiety effects in some patients through the norepinephrine reuptake inhibition, and removing the medication can produce a relative deficit in these effects. Patients with co-occurring depression or anxiety who were partially treated by the atomoxetine may find that the underlying mood condition becomes more prominent during and after the taper. This is one reason that coordination of care with mental health treatment is appropriate for patients with co-occurring conditions.

Sleep changes are common and can be in either direction. Many patients describe disturbed sleep with difficulty falling asleep and frequent waking in the first one to two weeks after stopping. Others describe increased sleepiness and need for more sleep than usual, reflecting the reversal of the modest stimulating effect that atomoxetine produces in many patients. Sleep hygiene measures including consistent bedtime, reduced screen time before bed, and a cool dark sleep environment can help manage these changes. Most sleep disturbances resolve within two to four weeks.

Timeline of return of ADHD symptoms

Patients should expect the return of the ADHD symptoms that were being treated, with the timeline depending on individual factors and on the speed of the taper. For a patient tapering over two to four weeks, the symptoms typically return progressively during the taper rather than appearing suddenly at the end. The patient may notice increased difficulty concentrating during the first dose reduction, more prominent inattention by the second reduction, and full return of baseline ADHD symptoms within a few weeks of the final dose.

Some patients find that the return of ADHD symptoms is more disabling than they remembered. This can occur for several reasons. The contrast with the treated state makes the untreated state feel worse than it would feel as a baseline. Life circumstances may have become more demanding during the treated period, so the demands on attention and executive function are now greater than they were before treatment started. Skills and habits that developed during treatment may have been propped up by the medication and may not have been adequately consolidated as independent capacities. Some patients in this situation choose to restart medication after a trial period off.

Other patients find that they manage well after discontinuation, particularly those whose ADHD symptoms were always relatively mild, those who developed strong behavioural and organisational skills during the treated period, those whose life circumstances have changed to be less demanding of attention, and those who have other supports including therapy, coaching, or environmental modifications. Successful discontinuation often involves continued attention to the strategies that supported function during the treated period rather than assuming that those strategies are no longer needed.

How to manage the discontinuation period safely

Several practical measures support successful discontinuation of atomoxetine. The first is timing the discontinuation to a period of relatively low demand on attention and function. Stopping during a busy work or school period, during a major life transition, or during a stressful period in family life is rarely the best timing. Many patients plan discontinuation for during a planned holiday or low-demand period when the return of ADHD symptoms can be managed with less impact on important obligations.

The second measure is ensuring that any co-occurring conditions including depression, anxiety, and substance use issues are stable and being addressed before discontinuation. Patients with co-occurring conditions are at higher risk of difficulty during the taper and benefit from coordination of care with mental health professionals. If the atomoxetine was treating both ADHD and a co-occurring mood or anxiety condition, the question of whether the mood or anxiety condition needs its own treatment after the atomoxetine is stopped should be addressed before the taper begins rather than during it.

The third measure is establishing what skills and supports will be in place after discontinuation. Behavioural strategies developed during ADHD treatment including time-blocking, written task management, environmental modifications, and structured routines can carry the patient through the post-medication period with much less difficulty than they would otherwise experience. Coaching for adults with ADHD, parenting support for parents of children with ADHD, and accommodations at school or work can all support successful post-medication function.

The fourth measure is having a clear plan for what to do if the discontinuation produces unmanageable symptoms or if the return of ADHD symptoms is more disabling than expected. The default plan should include contact with the prescribing clinician for assessment, and either restarting the medication, switching to an alternative medication, or proceeding with non-medication approaches as appropriate. Knowing that restarting is always an option reduces the anxiety associated with the taper and allows patients to engage with the trial off medication without feeling that the decision is irreversible.

Alternative ADHD treatments

Several alternatives are available for patients who are stopping Strattera but who continue to need ADHD treatment. Stimulant medications remain the first-line treatment for most patients with ADHD, with substantially better symptom control than atomoxetine in most clinical trials. The amphetamine class (Adderall, Vyvanse, Dyanavel) and the methylphenidate class (Ritalin, Concerta, Focalin, Quillivant) have similar efficacy and are typically chosen based on individual response, side effect profile, and duration of action needed. The trade-offs of stimulants include the controlled substance status, the abuse potential, the cardiovascular effects, and the appetite and sleep effects that some patients find difficult.

Non-stimulant alternatives to atomoxetine include guanfacine extended-release (Intuniv) and clonidine extended-release (Kapvay), both alpha-2 adrenergic agonists that improve ADHD symptoms through a different mechanism. These medications can be used alone or in combination with stimulants. Bupropion is sometimes used off-label for ADHD with some evidence of benefit, particularly in adults with co-occurring depression. Modafinil and armodafinil are sometimes used off-label but have less established evidence for ADHD specifically.

Non-medication approaches include behavioural therapy, particularly cognitive behavioural therapy adapted for ADHD, executive function coaching, time management training, environmental modifications, and structured exercise. The evidence base for these approaches is growing, and combination with medication generally produces better outcomes than either alone. For some patients, particularly those with mild ADHD, the non-medication approaches alone may be sufficient. For patients with more severe ADHD or with significant functional impairment, medication usually remains a part of the treatment plan.

Strattera in patients with substance use disorder

Atomoxetine is sometimes prescribed for patients with ADHD who also have substance use disorder, particularly stimulant use disorder, because the non-stimulant mechanism avoids the abuse potential of the stimulant ADHD medications. The clinical situation is complex because many patients with stimulant use disorder also have undiagnosed or undertreated ADHD that may have contributed to their substance use, and treatment of the ADHD can support recovery from the substance use disorder.

The decision between atomoxetine and stimulant medication for ADHD in patients with substance use disorder is individualised. Atomoxetine has the advantage of no abuse potential but the disadvantage of generally lower effectiveness. Long-acting stimulant formulations such as Vyvanse have less abuse potential than short-acting forms because the slow onset reduces the rewarding subjective effect, and can be used in patients with substance use disorder under careful supervision. The choice depends on the severity of the ADHD, the severity of the substance use disorder, the patient’s preferences, and the available supports.

Stopping atomoxetine in a patient with substance use disorder warrants particular attention to relapse risk. The return of untreated ADHD symptoms can drive return to stimulant or other substance use as patients self-medicate the symptoms. The discontinuation should be planned with attention to ensuring that ADHD treatment continues by other means if needed, and that recovery supports are intensified during the discontinuation period. Phuket Island Rehab provides residential addiction medicine treatment for international patients with co-occurring ADHD and substance use disorder, with attention to the medication management that supports both recovery from the substance use and ongoing treatment of the ADHD.

When alcohol use disorder is also part of the picture

Alcohol use disorder, the clinical term for what most people call alcoholism, frequently coexists with ADHD. The relationship is complex: untreated ADHD increases the risk of alcohol use disorder through several mechanisms including impulsivity, difficulty with emotion regulation, and the self-medication of attention and concentration difficulties with alcohol. Successful treatment of ADHD often reduces alcohol use to manageable levels, though for patients with established alcohol use disorder additional treatment specifically for the alcohol is usually needed.

Stopping atomoxetine in a patient with alcohol use disorder warrants attention to whether the medication has been helping with the alcohol use as well as with the ADHD. Some patients find that their drinking has become more manageable on ADHD medication, and discontinuation can produce a return of heavier drinking patterns. Coordinated care with both ADHD and addiction medicine perspectives produces the best outcomes for patients in this situation.

Treatment options for alcohol use disorder include medications such as naltrexone, acamprosate, and disulfiram, behavioural treatment with cognitive behavioural therapy or motivational enhancement therapy, and mutual aid groups such as Alcoholics Anonymous. Residential treatment is appropriate for patients with severe disease or for those who have not responded to outpatient care. The combination of effective ADHD treatment with effective alcohol use disorder treatment produces substantially better outcomes than either alone.

Summary

Stopping Strattera (atomoxetine) does not produce the severe withdrawal that follows discontinuation of stimulants, opioids, or benzodiazepines, but it can produce a discontinuation syndrome with mild to moderate symptoms including fatigue, sleep disturbance, mood changes, headache, and gastrointestinal upset, alongside the rebound return of the original ADHD symptoms. A gradual taper over two to four weeks under medical supervision is generally recommended for patients who have been on the medication for more than a few months, with the taper involving 25 to 50 percent dose reductions every five to seven days based on tolerability. The return of ADHD symptoms occurs progressively during the taper and is typically complete within two to four weeks of the final dose. Alternative ADHD treatments including stimulant medications, guanfacine, clonidine, and behavioural approaches can be initiated during or after the taper depending on individual circumstances. Patients with co-occurring conditions including depression, anxiety, and substance use disorder warrant particular attention during the discontinuation process. As Dr. Ponlawat Pitsuwan summarises, “Stopping Strattera is generally a straightforward clinical process compared with stopping medications that produce more severe dependence and withdrawal. The discontinuation symptoms are real but manageable, the timeline is predictable, and the question that usually matters most is what ADHD treatment will replace the atomoxetine if continued treatment is needed.”

Frequently asked questions

Do you need to taper off Strattera?

A taper is generally recommended for patients who have been on atomoxetine for more than a few months, particularly at higher doses. The taper protocol involves reducing the daily dose by 25 to 50 percent every five to seven days over two to four weeks. Patients on the medication for only a few weeks can often stop without a formal taper. The taper is recommended for tolerability rather than because of medical danger from abrupt discontinuation.

What are the side effects of stopping Strattera?

Discontinuation symptoms can include fatigue, sleep disturbance, irritability, mood swings, headache, dizziness, sweating, and gastrointestinal symptoms including nausea and abdominal discomfort. The original ADHD symptoms also return progressively as the medication is withdrawn. The symptoms are typically mild to moderate and resolve over one to four weeks. They are not medically dangerous in healthy adults.

How long does it take to feel normal after stopping Strattera?

Pharmacological discontinuation symptoms typically resolve within one to three weeks of completing the taper. The return of ADHD symptoms is essentially complete within two to four weeks. Mood and sleep typically return to baseline within four to six weeks. Patients who restart medication or who establish other ADHD treatments may not experience the full impact of discontinuation.

Is Strattera addictive?

No. Atomoxetine is not a controlled substance and does not produce the abuse potential or the classic dependence and withdrawal syndromes of the stimulant ADHD medications. The medication can produce a mild discontinuation syndrome reflecting brain adaptation but does not produce the compulsive use, craving, and reward-circuit changes that characterise true addiction.

Can I switch from Strattera to Adderall?

Yes. Switching from atomoxetine to a stimulant medication including Adderall, Vyvanse, Ritalin, or Concerta is common and can usually be done with a brief overlap period or with a short washout. The decision and the protocol should be coordinated with the prescribing clinician. Stimulant medications generally produce better ADHD symptom control than atomoxetine but carry their own risks including controlled substance status and abuse potential.

What if I miss a dose of Strattera?

Missed doses of atomoxetine should be taken as soon as remembered unless it is close to the time for the next dose, in which case the missed dose should be skipped. Doubling up is not appropriate because it does not improve the clinical effect and may produce more side effects. Occasional missed doses do not typically produce significant withdrawal symptoms because of the medication’s steady-state pharmacology, but consistent dosing produces the best clinical outcomes.

Sources

• U.S. Food and Drug Administration (FDA). Strattera (atomoxetine) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021411s050lbl.pdf
• Kratochvil CJ, Vaughan BS, Stoner JA, et al. A double-blind, placebo-controlled study of atomoxetine in young children with ADHD. Pediatrics. 2011;127(4):e862-e868. https://publications.aap.org/pediatrics/article/127/4/e862
• National Institute of Mental Health (NIMH). Attention-Deficit/Hyperactivity Disorder. https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd
• American Academy of Pediatrics. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019;144(4):e20192528. https://publications.aap.org/pediatrics/article/144/4/e20192528
• Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-738. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(18)30269-4/fulltext
• Substance Abuse and Mental Health Services Administration (SAMHSA). National Helpline. https://www.samhsa.gov/find-help/national-helpline
• National Institute on Drug Abuse (NIDA). Prescription Stimulants. https://nida.nih.gov/publications/drugfacts/prescription-stimulants

Strattera, atomoxetine, generic atomoxetine, ADHD, attention deficit hyperactivity disorder, attention deficit disorder, ADD, FDA, DEA, non-stimulant, controlled substance, norepinephrine reuptake inhibitor, NRI, selective norepinephrine reuptake inhibitor, norepinephrine transporter, dopamine, prefrontal cortex, executive function, working memory, impulsivity, inattention, hyperactivity, distractibility, restlessness, Adderall, mixed amphetamine salts, dextroamphetamine, amphetamine, Vyvanse, lisdexamfetamine, Ritalin, methylphenidate, Concerta, Focalin, dexmethylphenidate, Quillivant, Dyanavel, guanfacine, Intuniv, clonidine, Kapvay, alpha-2 adrenergic agonist, bupropion, modafinil, armodafinil, taper, discontinuation syndrome, withdrawal symptoms, rebound symptoms, fatigue, sleep disturbance, mood changes, irritability, headache, dizziness, sweating, nausea, abdominal pain, suicidal thinking, boxed warning, FDA pregnancy category C, depression, anxiety, alcohol use disorder, stimulant use disorder, substance use disorder, ADHD coaching, cognitive behavioural therapy, CBT, executive function coaching, NIMH, SAMHSA, NIDA, American Academy of Pediatrics, NHS, residential rehab, Phuket Island Rehab, addiction medicine, dual diagnosis.